. Author manuscript; available in PMC: 2019 Aug 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2018 Feb 21;16(8):1300–1306.e3. doi: 10.1016/j.cgh.2018.02.022

Table 3.

Temporal Association of Statin Use and Overall Mortality Among Patients With Pancreatic Cancer.

		Pre-diagnosis statin use
Time interval between reported statin use and cancer diagnosis	No. of cases	Non-regular use	Regular use	P value
	No. of cases	HR	HR (95% CI)^a
0–2 years	559	1 (referent)	0.84 (0.70–1.00)	.05
2–4 years	563	1 (referent)	0.87 (0.72–1.04)	.12
4–6 years	555	1 (referent)	0.84 (0.69–1.02)	.08
6–8 years	565	1 (referent)	0.82 (0.66–1.01)	.06
8–10 years	527	1 (referent)	0.93 (0.74–1.17)	.52
10–12 years	454	1 (referent)	0.95 (0.73–1.23)	.67

HR, hazard ratio.

The Cox proportional hazards model was adjusted for age at diagnosis (continuous), cohort (sex), race/ethnicity (white, black, other, or unknown), year of diagnosis (2000–2005 or 2006–2013), smoking status (never, past, current, or unknown), body mass index (continuous), and diabetes status (no, recent-onset, or long-standing).